Top announcements
Selected from the latest releases
Science|Prilenia and Ferrer
Prilenia and Ferrer Announce Authorization for EU Initiation of Confirmatory PRECISE-HD Study of Pridopidine in Huntington's Disease
October 22, 2026 · 4:34 AMPrilenia Therapeutics B.V. and Ferreri today announced that the confirmatory Phase 3 PRECISE-HD study of investigational pridopidine in Huntington's disease (HD…
Science|Ferrer and Prilenia
Ferrer and Prilenia Announce Authorization for EU Initiation of Confirmatory PRECISE-HD Study of Pridopidine in Huntington's Disease
October 22, 2026 · 3:00 AM
Science|IQM Quantum Computers
IQM Quantum Computers Announces Conference Call to Report Third Quarter 2026 Financial Results on November 5, 2026
October 22, 2026 · 2:00 AMLatest releases
View all →Science|Prilenia and Ferrer
Prilenia and Ferrer Announce Authorization for EU Initiation of Confirmatory PRECISE-HD Study of Pridopidine in Huntington's Disease October 22, 2026 · 4:34 AM
02
Science|Ferrer and Prilenia
Ferrer and Prilenia Announce Authorization for EU Initiation of Confirmatory PRECISE-HD Study of Pridopidine in Huntington's Disease October 22, 2026 · 3:00 AM
03
Science|IQM Quantum Computers
IQM Quantum Computers Announces Conference Call to Report Third Quarter 2026 Financial Results on November 5, 2026 October 22, 2026 · 2:00 AM
04
Science|Arcus Biosciences
Arcus Biosciences Announces Pricing of $250 Million Public Offering of Common Stock October 21, 2026 · 10:53 PMLatest from leading organizations
Explore recent announcements by organization
Browse the latest releases
Science|Prilenia and Ferrer
Prilenia and Ferrer Announce Authorization for EU Initiation of Confirmatory PRECISE-HD Study of Pridopidine in Huntington's Disease
Prilenia Therapeutics B.V. and Ferreri today announced that the confirmatory Phase 3 PRECISE-HD study of investigational pridopidine in Huntington's disease (HD) has received authorization to begin in participating EU Me…
October 22, 2026 · 4:34 AM
Science|Ferrer and Prilenia
Ferrer and Prilenia Announce Authorization for EU Initiation of Confirmatory PRECISE-HD Study of Pridopidine in Huntington's Disease
Ferrer and Prilenia Announce Authorization for EU Initiation of Confirmatory PRECISE-HD Study of Pridopidine in Huntington's Disease....
October 22, 2026 · 3:00 AM
Science|IQM Quantum Computers
IQM Quantum Computers Announces Conference Call to Report Third Quarter 2026 Financial Results on November 5, 2026
IQM Quantum Computers will host a conference call and live webcast on Thursday, November 5, 2026 to discuss its third-quarter 2026 financial results....
October 22, 2026 · 2:00 AMScience|Arcus Biosciences
Arcus Biosciences Announces Pricing of $250 Million Public Offering of Common Stock
Arcus Biosciences, Inc. (NYSE: RCUS), a late clinical-stage biopharmaceutical company focused on developing differentiated molecules and combinations for the treatment of cancer and immune diseases, today announced the p…
October 21, 2026 · 10:53 PMSpinalSyn: A More Practical Approach to Back Stimulation
Designed to make positioning easier, more consistent, and more convenient
SpinalSyn is a wearable back-stimulation system developed around one simple idea: electrical stimulation should be easier to use on areas of the back that can be difficult to reach and position accurately.
Instead of relying only on individually placed electrode pads, SpinalSyn uses a dedicated positioning rail to help organize the stimulation points along the back. This creates a more repeatable setup and reduces the need to recreate pad placement from scratch with every session.
Built Around Everyday Use
The system brings together the stimulation unit, electrode pads, wiring, and positioning structure in one coordinated setup. The focus is not on reinventing electrical stimulation itself, but on making the experience around it more practical and easier to incorporate into a regular wellness or recovery routine.
Easier positioning. More consistent placement. A simpler way to use electrical stimulation at home.
SpinalSyn article →